fda shortage semaglutide injection resolved feb 21 2025 GLP-1 Drugs: Removes from the Drug List Compounded Semaglutide & Tirzepatide 2025:

We are moving beyond the cycle of retinol /harsh acids burn and "inflammaging" to embrace a more sophisticated approach: Architectural Repair

Changes in lipid profiles may show decreased triglycerides and shifts in cholesterol levels, reflecting how tirzepatide affects fat metabolism

This approach may theoretically provide more complete CGRP blockade because it eliminates the ligand rather than competing with it at the receptor binding site

These proteins support muscle retention and keep hunger in check, making them a great fit for GLP-1 patients

Theres this huge educational journey that we need to take consumers on